AstraZeneca : Lynparza Combination Improves PFS In Phase III Ovarian Cancer Trial
5/4 08:34
(RTTNews) - British drug major AstraZeneca Plc (AZN, AZN.L) said results from an interim analysis of the DUO-O Phase III trial showed treatment with a combination of Lynparza (olaparib), Imfinzi (durvalumab), chemotherapy and bevacizumab demonstrated a statistically significant a...